Downregulation of SAV1 plays a role in pathogenesis of high-grade clear cell renal cell carcinoma
© Matsuura et al; licensee BioMed Central Ltd. 2011
Received: 7 July 2011
Accepted: 20 December 2011
Published: 20 December 2011
Clinical outcome of patients with high-grade ccRCC (clear cell renal cell carcinoma) remains still poor despite recent advances in treatment strategies. Molecular mechanism of pathogenesis in developing high-grade ccRCC must be clarified. In the present study, we found that SAV1 was significantly downregulated with copy number loss in high-grade ccRCCs. Therefore, we investigated the SAV1 function on cell proliferation and apoptosis in vitro. Furthermore, we attempted to clarify the downstream signaling which is regulated by SAV1.
We performed array CGH and gene expression analysis of 8 RCC cell lines (786-O, 769-P, KMRC-1, KMRC-2, KMRC-3, KMRC-20, TUHR4TKB, and Caki-2), and expression level of mRNA was confirmed by quantitative RT-PCR (qRT-PCR) analysis. We next re-expressed SAV1 in 786-O cells, and analyzed its colony-forming activity. Then, we transfected siRNAs of SAV1 into the kidney epithelial cell line HK2 and renal proximal tubule epithelial cells (RPTECs), and analyzed their proliferation and apoptosis. Furthermore, the activity of YAP1, which is a downstream molecule of SAV1, was evaluated by western blot analysis, reporter assay and immunohistochemical analysis.
We found that SAV1, a component of the Hippo pathway, is frequently downregulated in high-grade ccRCC. SAV1 is located on chromosome 14q22.1, where copy number loss had been observed in 7 of 12 high-grade ccRCCs in our previous study, suggesting that gene copy number loss is responsible for the downregulation of SAV1. Colony-forming activity by 786-O cells, which show homozygous loss of SAV1, was significantly reduced when SAV1 was re-introduced exogenously. Knockdown of SAV1 promoted proliferation of HK2 and RPTEC. Although the phosphorylation level of YAP1 was low in 786-O cells, it was elevated in SAV1-transduced 786-O cells. Furthermore, the transcriptional activity of the YAP1 and TEAD3 complex was inhibited in SAV1-transduced 786-O cells. Immunohistochemistry frequently demonstrated nuclear localization of YAP1 in ccRCC cases with SAV1 downregulation, and it was preferentially detected in high-grade ccRCC.
Taken together, downregulation of SAV1 and the consequent YAP1 activation are involved in the pathogenesis of high-grade ccRCC. It is an attractive hypothesis that Hippo signaling could be candidates for new therapeutic target.
KeywordsClear cell renal cell carcinoma SAV1 Hippo pathway
Renal cell carcinoma (RCC) is histopathologically subdivided into various categories, of which clear cell renal cell carcinoma (ccRCC) is the most common subtype, accounting for 70-80% of all RCCs . Fuhrman's nuclear grading system is used as a reliable prognostic indicator for ccRCCs , and it is widely accepted that the clinical outcome of patients with high-grade ccRCC remains poor despite recent advances in treatment strategies [3–6]. Therefore, it is important to clarify the pathogenesis of high-grade ccRCC in order to develop new treatments for improving the prognosis of affected patients. However, differences in the molecular mechanisms of pathogenesis between low-grade and high-grade ccRCCs remain to be determined.
We have previously reported the presence of chromosomal copy number aberrations (CNAs) in ccRCC determined using array-based CGH analysis . In our previous study, 14q loss was observed in 7 of 12 high-grade ccRCCs, but in only 1 of 10 low-grade ccRCCs, suggesting that 14q loss is important for the development of the former. Furthermore, we had previously found that genes located at 14q with copy number loss tended to be downregulated, suggesting that copy number loss at 14q in high-grade ccRCC is responsible for the downregulation of genes located in this region, and that putative tumor suppressor genes may be present at this chromosomal locus . However, the genes concerned at 14q have not yet been identified.
In the present study, we attempted to identify genes that are downregulated as a result of copy number loss at 14q by using ccRCC cell lines in addition to clinical samples. We found that the SAV1 gene, a human homolog of salvador, which is known to be a tumor suppressor in Drosophila , was significantly downregulated in ccRCCs with 14q loss. Further analysis of SAV1 function revealed that it is a putative tumor suppressor gene in high-grade ccRCCs.
The renal cell carcinoma cell lines 786-O (#CRL-1932), 769-P (#CRL-1933) and Caki-2 (#HTB-47), and the human cell line HK2 (#CRL-1427), were purchased from the American Type Culture Collection (ATCC) (Rockville, MD). KMRC-1, KMRC-2, KMRC-3, and KMRC-20 were purchased from JCRB (Osaka, Japan), and TUHR4TKB was provided by RIKEN BRC through the National Bio-Resource Project of MEXT, Japan. RPTEC was purchased from Lonza Walkersville Inc. (Walkersville, MD). All cell lines were maintained in accordance with the supplier's instructions.
Tissue samples and histopathological examination
Primary ccRCCs were surgically resected at Oita University Hospital, and diagnosed histopathologically as described previously . Information on the other 98 patients is summarized in Additional file 1: Table S1. Use of the tissue samples for all experiments was approved by all the patients and by Oita University Ethics Committee (Approval No. P-05-05).
Immunohistochemistry of paraffin-embedded RCC tissue sections was performed in a similar way to that used in our previous work . Anti-SAV1 antibody (clone 3B320; Abnova, Taipei, Taiwan) and anti-YAP antibody (Cell Signaling Technology, Danvers) were used as the primary antibodies.
Quantitative RT-PCR was performed with a Universal probe library (Roche Diagnostics, Mannheim, Germany) and LightCycler 480 probe master (Roche Diagnostics) by the Taqman method as described previously . Levels of messenger RNA expression relative to KPNA6 were obtained from a standard curve. We used KPNA6 as a control in this study because KPNA6 expression was not statistically different among the ccRCC and non-neoplastic tissues, although expression levels of known markers such as beta-2-microgloblin and glyceraldehydes 3-phosphate dehydrogenase (GAPDH) were variable across the samples .
Lentiviral vector production and in vitro transduction
The full-length SAV1 cDNA was obtained from NBRC (NITE Biological Resource Center, Chiba, Japan), cloned into pLenti7.3/V5-DEST (Invitrogen, Carlsbad, CA, USA) using the Gateway system™ in accordance with the manufacturer's instructions, and used to generate the vector SAV1-pLenti7.3/V5-DEST (pLenti-SAV1). Transient transfections of the pLenti7.3/V5-DEST empty vector and pLenti-SAV1 with ViraPower Packaging Mix (Invitrogen) into HEK293T cells were performed using Lipofectamine2000 (Invitrogen) in accordance with the manufacturer's instructions. After 48 h, the viral supernatants were collected, filtered, and enriched by ultracentrifugation. Subsequently, transduction of target cells was performed at an optimized multiplicity of infection (MOI) of 5 with Polybrene at a final concentration of 6.0 μg/ml. To identify stable clones of SAV1-re-expressing cells, the full-length SAV1 cDNA was cloned into pLenti6.3/V5-DEST (Invitrogen). Lentivirus expressing SAV1 was generated as described above. 786-O cells were transduced with SAV1-pLenti6.3/V5-DEST or the pLenti6.3/V5-DEST vector, respectively. After transduction and selection with 0.5 μg/ml blasticidin (Invitrogen), two independent clones for SAV1 were obtained, and designated as SAV1-1 and SAV1-2. Control cells were also generated using the pLenti6.3/V5-DEST empty vector.
Colony formation assay
One day after transduction of 786-O or 769-P cells with lentivirus expressing SAV1, one fiftieth of the cells were reseeded on 100-mm dishes and cultured. When colonies became visible, they were stained with Giemsa for 30 min, rinsed with water, and counted.
Cells were transfected with Stealth™ RNAi oligonucleotide or the Stealth™ RNAi Negative Control Duplex with the corresponding GC content (Invitrogen) at a final concentration of 10 nM using Lipofectamine RNA-MAX (Invitrogen) in accordance with the manufacturer's instructions.
After transfection of siRNAs in a 96-well plate, MTS assay was carried out using the CellTiter 96RAQueous One Solution Cell Proliferation Assay Kit (Promega, Madison, WI, USA), and the optical density was measured at 492 nm using a fluorescence reader (Tecan SpectraFluor) (Tecan, Crailsheim, Germany). In addition, BrdU incorporation was performed using a Cell Proliferation ELISA Kit (Roche Applied Science, Mannheim, Germany) in accordance with the manufacturer's protocols.
Cells were transfected with siRNA in a 96-well plate and cultured for 72 h. Nuclear morphology was then evaluated for apoptosis. DNA fragmentation was detected in the 96-well format using Cell Death Detection ELISA plus (Roche Applied Science) in accordance with the manufacturer's instructions. The activity of caspase 3 and caspase 7 was detected in the 96-well format by using the caspase-Glo 3/7 Assay (Promega) according to the manufacturer's instructions.
Western blot analysis
Western blot analysis was performed similarly to that in our previous study . In each analysis, 10 μg of cell lysate was used. The primary antibodies employed were: anti-human GAPDH antibody (Sigma-Aldrich), anti-SAV1 antibody (Cell Signaling Technology), anti-phosphorylated YAP antibody (Ser127; Cell Signaling Technology), and anti-YAP antibody (Santa Cruz Biotechnology). Detection was performed with ECL Western Blotting Detection Reagents (Amersham Biosciences, Piscataway, NJ, USA) in accordance with the manufacturer's instructions.
Dual luciferase assay
For the luciferase reporter assay, stable clones of 786-O cells (5 × 104) were seeded in 6-well plates, and then co-transfected with 0.5 μg of pGL4.35 (9xUAS Gal4) and GAL4-TEADs, respectively, using Lipofectamine Plus (Invitrogen). At 48 h after transfection, the cells were lysed and luciferase activity was assayed using a Dual-luciferase Reporter Assay kit (Promega) in accordance with the manufacturer's instructions. All luciferase activities were normalized to the Renilla luciferase reporter pRL-CMV plasmid (Promega).
Quantitative RT-PCR data were analyzed statistically by the Mann-Whitney U-test. The two-sided Student's t test and Fisher's exact test was used to analyze differences in experimental data obtained from the cell lines. Differences at P < 0.05 were considered statistically significant.
Additional methods are described in Supplementary methods (Additional file 2: Methods S1)
SAV1 is downregulated in RCCs with copy number loss at 14q22.1
We performed array CGH analysis and gene expression analysis of 8 RCC cell lines (786-O, 769-P, KMRC-1, KMRC-2, KMRC-3, KMRC-20, TUHR4TKB, and Caki-2) in order to identify downregulated genes located in the region of 14q loss (Additional file 3: Figure S1a, ). All the data obtained in the array CGH and expression microarray analysis are available at DDBJ via CIBEX (http://cibex.nig.ac.jp/index.jsp), under accession numbers CBX97 for array CGH, and CBX96 for expression-microarray. Copy number loss at 14q was detected in all the cell lines analyzed. Detailed analysis of the region of copy number loss at 14q revealed two different homozygous deletions at 14q in 3 (786-O, 769-P, KMRC-1) of the 8 cell lines.
Impact of SAV1 protein expression and nuclear grade in ccRCC
weak or negative
Fisher's exact test
p = 0.0469
SAV1 inhibits colony formation and cell proliferation
Downregulation of SAV1 activates YAP
It has been reported that unphosphorylated YAP1 binds to members of the TEAD family, including TEAD1, 2, 3 and 4, and plays a functional role as a transcriptional co-activator . Therefore, we next examined whether SAV1 affects the transcriptional activity of the YAP1-TEAD complex in RCCs. SAV1-transduced 786-O cells were transfected with expression plasmids encoding a Gal4 DNA binding domain fused to TEAD1, TEAD2, and TEAD3 (Gal4-TEADs), a Gal4-9x UAS luciferase reporter (pGL4.31) and pRL-CMV (Figure 4c) (Additional file 9: Figure S7). In control cells, co-transfection of the Gal4-TEAD3 and Gal4-9x UAS luciferase reporter led to an increase in luciferase activity. On the other hand, in SAV1-transduced 786-O cells, the luciferase activity eventually decreased, suggesting that, in RCCs with suppression of Hippo signaling, YAP1 activity is significantly elevated (Figure 4c).
Immunohistochemical staining of SAV1 and YAP1 protein in ccRCC
weak or negative
Fisher's exact test
p < 0.001
Impact of subcellular localization of YAP1 protein and nuclear grade in ccRCC
Fisher's exact test
p = 0.0445
The Hippo pathway is known to control organ size both in Drosophila and mammalian tissues, and many studies of the tumor suppressor function of the Hippo pathway have been reported [13, 17, 20–22]. In the present study, we found that SAV1 downregulation caused by 14q loss conferred a survival and growth advantage on RCCs. It has already been reported that the SAV1 gene is homozygously deleted in two RCC cell lines . However, it has not been clarified whether the same abnormalities actually occur in patients with RCCs. Therefore, our present data appear to provide strong support for the hypothesis that the SAV1 gene may be a potential tumor suppressor of RCC. Furthermore, SAV1 has been reported to act as a tumor suppressor in cancers other than RCC. For example, two groups have recently reported that conditional knockout mice, in which the SAV1 gene was deleted only in the liver, developed hepatocellular carcinoma (HCC) [23, 24], suggesting that deletion of the SAV1 gene is responsible for the development of such carcinomas. Therefore, we propose that the SAV1 gene is also involved in tumorigenesis of ccRCC.
In the present study, we found that knockdown of SAV1 induced significant inhibition of apoptosis in immortalized kidney cell line, HK2. It has previously been reported that apoptosis was inhibited in sav-mutated eye imaginal disc of Drosophilla . Furthermore, in SAV1 gene-disrupted mice, apoptotic keratinocytes of epidermis was found to be significantly reduced compared with wild type mice . Thus, on the basis of our present data in addition to the previous reports, it is suggested that downregulation of SAV1 may play an important role in inhibiting apoptosis in RCC.
On the other hand, in the present study, the increase of cell proliferation by SAV1 downregulation was relatively modest. With respect to interpretation of this result, we cannot rule out the possibility that the data indicating the increase of cell proliferation shown by MTS assay and BrdU-incorporation study may be affected by the significant inhibition of apoptosis caused by SAV1 knockdown. It has been reported that BrdU incorporation was significantly increased in liver of SAV1 gene-disrupted mice . However, another group has reported that the increase of proliferation of embryonic keratinocytes isolated from SAV1-null mice was comparable to that of wild type . Further study is needed to clarify whether SAV1 downregulation is really responsible for cell proliferation in RCC.
We have previously reported that loss of 14q was observed more frequently in cases of high-grade ccRCC than in low-grade ccRCC . Since it has been reported that the prognosis of patients with high-grade ccRCCs is markedly poor, loss of 14q is suggested to be involved in the malignant phenotype of high-grade ccRCC . In the present study, SAV1 downregulation was confined to high-grade ccRCCs with copy number loss at 14q encompassing 14q22.1. Although we cannot rule out the possibility that tumor suppressor genes other than SAV1 may exist at 14q, we speculate that suppression of the Hippo pathway caused by downregulation of SAV1 is involved in the development of high-grade ccRCCs.
It has been reported that YAP1 is a transcriptional regulator and acts as a oncoprotein in various carcinomas [26–30]. Indeed, when YAP1 is hypophosphorylated due to suppression of the Hippo signaling pathway including SAV1, it translocates from the cytoplasm to the nucleus and binds to various transcription factors [16, 17, 25]. An experiment using conditional knockout mice in which the SAV1 gene was deleted only in the liver and YAP1 was specifically activated in oval cells has clearly shown that SAV1 is required for inactivation of YAP1 . In the present study, we found that phosphorylation of YAP1 was suppressed in SAV1-deficient RCC cell lines and that phosphorylation of YAP1 was enhanced in 786-O cells when SAV1 was re-expressed. Furthermore, YAP1 tended to translocate to the nucleus in SAV1-downregulated ccRCCs as well as in high-grade ccRCCs. These findings suggest that activation of YAP1 due to downregulation of SAV1 is involved in the pathogenesis of high-grade ccRCCs.
Recently, Zhao et al. reported that the transcription factor TEAD binds to YAP, and that the resulting YAP1-TEAD complex is required for YAP-induced cell growth and epithelial mesenchymal transition (EMT) . We found that the transcriptional activity of TEAD-YAP was repressed when SAV1 was re-expressed in SAV1-deficient 786-O cells, suggesting that TEAD-YAP may play functional roles in the regulation of cell proliferation in RCC. However, at this stage, the transcriptional targets of the TEAD-YAP transcription factor complex in RCCs are still unclear. In order to clarify the molecular mechanisms involved in the development of high-grade RCCs, it will be necessary to identify the transcriptional target genes of the TEAD-YAP1 complex in RCCs. Because the prognosis of patients with high-grade ccRCC remains poor, it is an attractive hypothesis that unidentified molecules that are activated by suppressed Hippo signaling could be candidates for consideration in the development of new therapeutic drugs for high-grade ccRCCs. Further studies will be required to address this possibility.
We show that SAV1, a component of the Hippo pathway, was frequently downregulated in high-grade ccRCC in association with copy number loss of chromosome 14q22.1, where the SAV1 gene is located. In addition to these studies using ccRCC samples, we examined the functional significance of SAV1 in cell lines. The results indicated that the downregulation of SAV1 promoted cell proliferation and inhibited apoptosis in ccRCC. In addition, YAP1 tended to be located in the nucleus in ccRCC cases with SAV1 downregulation, and it was preferentially detected in high-grade ccRCC. On the bases of these findings, downregulation of SAV1 and the consequent YAP1 activation are involved in the pathogenesis of high-grade ccRCC.
Salvador homolog 1
Clear cell renal cell carcinoma
Large tumor suppressor
- TEAD TEA:
Domain family member
Copy number aberration
Comparative genomic hybridization
Hypoxia inducible factor
Renal proximal tubule epithelial cells
Mammalian sterile STE20-like kinase
This work was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports Science and Technology of Japan. We thank to Dr. B. Zhao, University of Michigan, USA, for providing the plasmids Gal4-TEADs. We also thank T. Iwao, K. Nakao, M. Koya, M. Hirose and J. Itai for technical support.
- Reuter VE: The pathology of renal epithelial neoplasms. Semin Oncol. 2006, 33 (5): 534-543. 10.1053/j.seminoncol.2006.06.009.PubMedView Article
- Fuhrman SA, Lasky LC, Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982, 6 (7): 655-663. 10.1097/00000478-198210000-00007.PubMedView Article
- Bretheau D, Lechevallier E, de Fromont M, Sault MC, Rampal M, Coulange C: Prognostic value of nuclear grade of renal cell carcinoma. Cancer. 1995, 76 (12): 2543-2549. 10.1002/1097-0142(19951215)76:12<2543::AID-CNCR2820761221>3.0.CO;2-S.PubMedView Article
- Cambell SCNA, Bukowski RM: Renal tumors. Cambell-Walsh UROLOGY. Edited by: Wein AJ KL, Novick AC, Partin AW, Peters CA. 2007, Philadelphia: Saunders, 1567-1637. 9
- Lane BR, Babineau D, Kattan MW, Novick AC, Gill IS, Zhou M, Weight CJ, Campbell SC: A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. J Urol. 2007, 178 (2): 429-434. 10.1016/j.juro.2007.03.106.PubMedView Article
- Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, et al: Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005, 23 (12): 2763-2771.PubMedView Article
- Yoshimoto T, Matsuura K, Karnan S, Tagawa H, Nakada C, Tanigawa M, Tsukamoto Y, Uchida T, Kashima K, Akizuki S, et al: High-resolution analysis of DNA copy number alterations and gene expression in renal clear cell carcinoma. J Pathol. 2007, 213 (4): 392-401. 10.1002/path.2239.PubMedView Article
- Tapon N, Harvey KF, Bell DW, Wahrer DC, Schiripo TA, Haber DA, Hariharan IK: salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell. 2002, 110 (4): 467-478. 10.1016/S0092-8674(02)00824-3.PubMedView Article
- Matsuura K, Uesugi N, Hijiya N, Uchida T, Moriyama M: Upregulated expression of cardiac ankyrin-repeated protein in renal podocytes is associated with proteinuria severity in lupus nephritis. Hum Pathol. 2007, 38 (3): 410-419. 10.1016/j.humpath.2006.09.006.PubMedView Article
- Nakada C, Matsuura K, Tsukamoto Y, Tanigawa M, Yoshimoto T, Narimatsu T, Nguyen LT, Hijiya N, Uchida T, Sato F, et al: Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J Pathol. 2008, 216 (4): 418-427. 10.1002/path.2437.PubMedView Article
- Kosari F, Parker AS, Kube DM, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Vasmatzis G: Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res. 2005, 11 (14): 5128-5139. 10.1158/1078-0432.CCR-05-0073.PubMedView Article
- Shomori K, Nagashima Y, Kuroda N, Honjo A, Tsukamoto Y, Tokuyasu N, Maeta N, Matsuura K, Hijiya N, Yano S, et al: ARPP protein is selectively expressed in renal oncocytoma, but rarely in renal cell carcinomas. Mod Pathol. 2007, 20 (2): 199-207. 10.1038/modpathol.3800730.PubMedView Article
- Harvey K, Tapon N: The Salvador-Warts-Hippo pathway--an emerging tumour-suppressor network. Nat Rev Cancer. 2007, 7 (3): 182-191. 10.1038/nrc2070.PubMedView Article
- Harvey KF, Pfleger CM, Hariharan IK: The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell. 2003, 114 (4): 457-467. 10.1016/S0092-8674(03)00557-9.PubMedView Article
- Wu S, Huang J, Dong J, Pan D: hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell. 2003, 114 (4): 445-456. 10.1016/S0092-8674(03)00549-X.PubMedView Article
- Zhao B, Lei QY, Guan KL: The Hippo-YAP pathway: new connections between regulation of organ size and cancer. Curr Opin Cell Biol. 2008, 20 (6): 638-646. 10.1016/j.ceb.2008.10.001.PubMedPubMed CentralView Article
- Zhao B, Li L, Lei Q, Guan KL: The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev. 2010, 24 (9): 862-874. 10.1101/gad.1909210.PubMedPubMed CentralView Article
- Vassilev A, Kaneko KJ, Shu H, Zhao Y, DePamphilis ML: TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev. 2001, 15 (10): 1229-1241. 10.1101/gad.888601.PubMedPubMed CentralView Article
- Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, Lin JD, Wang CY, Chinnaiyan AM, et al: TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008, 22 (14): 1962-1971. 10.1101/gad.1664408.PubMedPubMed CentralView Article
- Kango-Singh M, Singh A: Regulation of organ size: Insights from the Drosophila Hippo signaling pathway. Dev Dyn. 2009, 238 (7): 1627-1637. 10.1002/dvdy.21996.PubMedView Article
- Cai J, Zhang N, Zheng Y, de Wilde RF, Maitra A, Pan D: The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev. 2010, 24 (21): 2383-2388. 10.1101/gad.1978810.PubMedPubMed CentralView Article
- Pan D: The hippo signaling pathway in development and cancer. Dev Cell. 2010, 19 (4): 491-505. 10.1016/j.devcel.2010.09.011.PubMedPubMed CentralView Article
- Lee KP, Lee JH, Kim TS, Kim TH, Park HD, Byun JS, Kim MC, Jeong WI, Calvisi DF, Kim JM, et al: The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci USA. 2010, 107 (18): 8248-8253. 10.1073/pnas.0912203107.PubMedPubMed CentralView Article
- Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q, Wang Y, Halder G, Finegold MJ, Lee JS, et al: Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci USA. 2010, 107 (4): 1437-1442. 10.1073/pnas.0911427107.PubMedPubMed CentralView Article
- Lee JH, Kim TS, Yang TH, Koo BK, Oh SP, Lee KP, Oh HJ, Lee SH, Kong YY, Kim JM, et al: A crucial role of WW45 in developing epithelial tissues in the mouse. Embo J. 2008, 27 (8): 1231-1242. 10.1038/emboj.2008.63.PubMedPubMed CentralView Article
- Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A, Pan D: Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007, 130 (6): 1120-1133. 10.1016/j.cell.2007.07.019.PubMedPubMed CentralView Article
- Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D, Montgomery EA, Anders RA: Expression of Yes-associated protein in common solid tumors. Hum Pathol. 2008
- Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, et al: Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 2006, 125 (7): 1253-1267. 10.1016/j.cell.2006.05.030.PubMedPubMed CentralView Article
- Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, et al: Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007, 21 (21): 2747-2761. 10.1101/gad.1602907.PubMedPubMed CentralView Article
- Hall CA, Wang R, Miao J, Oliva E, Shen X, Wheeler T, Hilsenbeck SG, Orsulic S, Goode S: Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res. 2010, 70 (21): 8517-8525. 10.1158/0008-5472.CAN-10-1242.PubMedPubMed CentralView Article
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/11/523/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.